Pebble Biotechnology develops ex-vivo living organ systems using surplus porcine organs to facilitate rapid preclinical testing of therapies without the use of laboratory animals. This approach provides researchers with high-fidelity physiological data, accelerating the progression of drug and device development while maintaining ethical standards.
Funding
$230K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional preclinical drug and device testing relies heavily on animal models, which can be costly, time-consuming, and ethically problematic, while often failing to accurately predict human physiological responses. This creates a bottleneck in the development pipeline, delaying the availability of new therapies and increasing overall R&D expenses.
Solution
Pebble Biotechnology Laboratories offers ex-vivo LIVING-ORGAN systems using surplus porcine organs to provide a physiologically relevant platform for rapid and ethical preclinical testing. Their technology maintains organ and tissue function outside the body with high fidelity, enabling researchers to evaluate the efficacy and safety of novel therapies in a human-relevant environment. By utilizing organs that would otherwise be discarded, Pebble eliminates the need for animal models in many preclinical studies, accelerating the development process and generating submission-ready data for clinical trial approval. The platform supports iterative testing and refinement of therapies while maintaining confidentiality.
Target Audience
The primary target audience includes pharmaceutical companies, medical device manufacturers, and research institutions seeking to accelerate preclinical testing, reduce reliance on animal models, and obtain high-fidelity physiological data for drug and device development.
Features
- Ex-vivo LIVING-ORGAN systems that mimic human physiology for accurate preclinical testing
- Utilization of surplus porcine organs, eliminating the need for animal models and adhering to ethical research practices
- Disease and therapy area agnostic platform applicable to various medical fields
- Streamlined service accelerating the progression of products from early testing to clinical trials
- Drug Evaluation Hub offering preclinical testing tools for drug refinement
- Capability to generate submission-ready data for regulatory approval
- Confidential and iterative testing environment allowing for therapy refinement without mandatory reporting
- Options for kidney, liver, limb, eye, multi-organ, dermatological, transplant, and cell and gene therapy studies